msf kwazulu-natal, south africa: bending the curves of hiv ... · operational research day,...
TRANSCRIPT
-
OPERATIONAL RESEARCH DAY, Brussels – 31 May 2019
MSF KwaZulu-Natal, South Africa: Bending the Curves of HIV & TB
2011-2018
Nolwenn Conan, Erica Simons, Liesbet Ohler, Ellie FordKamara, Maphalala Thembelihle, Linda Dlamini, Amir Shroufi, Gilles van Cutsem, Laura Trivino-
Duran , Menard L. Chihana, Helena Huerga,
-
OPERATIONAL RESEARCH DAY, Brussels – 31 May 2019
KZN Project: “Bending the curves” since
2011;
Aim to reduce HIV/TB incidence and
morbidity/mortality;
Impact Surveys in 2013 and 2018
Tshwane
Cape Town
Mbongolwane
Eshowe
Bending the curves
-
VL
Retain
Adhere
Treat
Link
Test
Prevent
HEA
LTH
PRO
MO
TIO
N, M
&E,
ADV
OCA
CY,
COM
MU
NIT
Y M
OBI
LISA
TIO
N, M
ENTO
RIN
G, L
AB
SUPP
ORT
, LO
GIS
TIC
SUPP
ORT
OPERATIONAL RESEARCH DAY, Brussels – 31 May 2019
-
OPERATIONAL RESEARCH DAY, Brussels – 31 May 2019
Prevention efforts
• Condom Distribution at Facilities and communities (Coloured Flavoured Condoms)
• MMC support • Schools: SRH Education • CHAPs/Health Promotion
-
OPERATIONAL RESEARCH DAY, Brussels – 31 May 2019
1st 90: Ensuring that 90% of people with HIV know their status
-
OPERATIONAL RESEARCH DAY, Brussels – 31 May 2019
• Initiation counseling; • Introduction of nurses
trained in integrated management of ARTs
2nd 90: Ensuring that 90% of people with HIV are on treatment
-
OPERATIONAL RESEARCH DAY, Brussels – 31 May 2019
3rd 90: Ensuring that 90% of people with HIV on treatment have viral suppression
• Mentoring of National Adherence Guidelines
• Community-based differentiated models of care
-
OPERATIONAL RESEARCH DAY, Brussels – 31 May 2019
Results of 2nd Population based survey
1st 90 2nd 90 3rd 90*
2013 76% 70% 93%
+14% +25% +1%
2018 90% 95% 94%
1st 90 2nd 90 3rd 90*
2018 85% 71% 88%
Comparison with national statistics (SABSSM V)
-
OPERATIONAL RESEARCH DAY, Brussels – 31 May 2019
Women Men
Chart1
Aware HIV+ statusAware HIV+ statusAware HIV+ status
On ARTOn ARTOn ART
Viral Load < 1,000 copies/mlViral Load < 1,000 copies/mlViral Load < 1,000 copies/ml
15-29
30-44
45- 59
%
0.861
0.928
0.962
0.789
0.8815
0.962
0.757
0.882
0.962
909090
Cascade of care (%)15-59 years
20132018
AllWomenMenAllWomenMen
HIV +100%100%100%100%100%100%
Aware of HIV Status76.4%74.1- 78.679.0%76.4- 81.468.3%63.1- 73.1%89.7%87.5- 91.591.9%89.6- 93.882.5%76.7- 87.1
Linked to care71.0%68.6- 73.473.4%71.6- 76.960.4%54.2- 66.1%88.5%86.1- 90.491.1%88.7- 93.179.9%73.8- 84.9
In Care62.7%59.8- 65.666.5%63.5- 69.350.6%44.6- 56.6%84.5%81.9- 86.788.3%85.6- 90.672.1%65.5- 77.8
On ART (test and treat)53.5%50.6- 56.355.7%52.8- 58.546.3%40.5- 52.3%84.1%81.5- 86.487.9%85.1- 90.272.1%65.5- 77.8
Viral Load < 1,000 copies/ml57.4%54.6- 60.160.3%57.4- 63.147.9%41.7- 54.1%83.9%81.3- 86.387.2%84.3- 89.673.3%66.7- 79.1
20132018
HIV +100%100%
Aware of HIV Status76.4%89.7%
Linked to care71.0%88.5%
In Care62.7%84.5%
On ART (test and treat)53.5%84.1%
Viral Load < 1,000 copies/ml57.4%83.9%
OverallWomenMen
909090909090909090
%95%CI%95%CI%95%CI%95%CI%95%CI%95%CI%95%CI%95%CI%95%CI
201376.474.1- 78.669.967.0- 72.793.191.0- 94.879.076.4- 81.470.567.7- 73.293.491.1- 95.168.363.1- 73.1%67.960.8- 74.292.186.0- 95.7
201889.787.5- 91.593.593.5- 96.994.492.4- 95.991.989.6- 93.895.593.5- 96.995.092.8- 96.582.576.7- 87.186.480.3- 90.892.386.5- 95.7
2013 results1st 9076.4% (95% CI: 74.1–78.6)
2nd 9069.9% (95% CI: 67.0–72.7)
3rd 9093.1% (95% CI: 91.0–94.8)
909090
2013
2018
Sheet3
Aware HIV+ statusWomenMenlinked to careWomenMenIn careWomenMenOn ARTWomenMenViral Load < 1,000 copies/mlWomenMen
15-1985.2%66.5- 94.369.2%40.7- 88.115-1982.1%63.6- 92.469.2%40.7- 88.115-1982.1%63.6- 92.469.3%40.7- 88.115-1982.1%63.6- 92.469.2%40.7- 88.115-1973.1%53.2- 86.658.3%30.6- 81.7
20-2483.3%72.3- 90.560.0%19.8- 90.120-2481.5%70.2- 89.275.0%23.5- 96.720-2475.4%63.5- 84.475.0%23.5- 96.720-2473.9%61.9- 83.175.0%23.5- 96.720-2473.3%60.8- 83.066.7%15.1- 95.7
25-2988.5%79.9- 93.755.6%32.9- 76.125-2987.4%78.6- 92.955.6%32.9- 76.125-2982.8%73.3- 89.327.8%12.0- 52.125-2981.6%72.0- 88.427.8%11.9- 52.125-2978.3%68.2- 85.946.7%23.9- 70 9
30-3488.6%81.3-93.383.3%67.4- 92.430-3488.5%81.2- 93.283.3%67.4- 92.430-3485.8%78.1- 91.275.0%58.4- 86.530-3485.8%78.1- 91.275.0%58.4- 86.530-3484.1%75.9- 89.971.4%54.4- 84.0
35-3995.7%89.1- 98.485.4%70.9- 93.335-3992.5%85.0- 96.480.0%64.7- 89.735-3991.3%83.5- 95.675.0%59.3- 86.135-3991.3%83.5- 95.675.0%59.3- 86.135-3989.1%81.0- 94.177.5%62.0- 87.9
40-4495.2%87.8- 98.284.6%65.3- 94.240-4495.5%87.8- 98.280.8%61.1- 91.840-4489.0%80.2- 94.273.1%53.1- 86.740-4487.8%78.8- 93.373.1%53.1- 86.740-4492.5%84.3- 96.675.0%54.2- 88.4
45-4994.1%85.3- 97.892.3%73.7- 98.145-4994.1%85.3- 87.884.6%65.3- 94.245-4994.1%85.3- 97.876.9%57.1- 89.345-4994.1%85.3- 97.876.9%57.1- 89.345-4995.5%87.0- 98.676.0%55.7- 88.9
50-5498.6%90.4- 99.886.4%65.0- 95.650-5498.6%90.4- 99.886.4%65.0- 95.650-5497.1%89.1- 99.381.8%60.2- 93.150-5497.1%89.1- 99.381.8%60.2- 93.150-5497.1%89.1- 99.381.8%60.2- 94.2
55-5995.9%85.1- 99.094.7%70.3- 99.355-5997.9%86.6- 99.789.5%66.0- 97.455-5997.9%86.6- 99.784.2%60.6- 94.955-5997.9%86.6- 99.784.2%60.6- 94.955-5995.8%84.8- 99.084.4%60.6- 94.9
60-6496.2%77.1- 99.5100.0%60-6492.3%73.9- 98.1100.0%60-6492.3%73.9- 98.1100.0%60-6492.3%73.9- 98.1100.0%60-64100.0%100.0%
65-6988.5%69.7- 96.281.8%49.0- 95.565-6992.3%73.9- 98.181.8%49.0- 95.565-6992.3%73.9- 98.181.8%49.0- 95.565-6992.3%73.9- 98.181.8%49.0- 95.565-6992.3%73.9- 98.181.8%49.0- 95.5
70-7466.7%15.3- 95.7100.0%70-7466.7%15.3- 95.7100.0%70-7466.7%15.3- 95.7100.0%70-7466.7%15.3- 95.7100.0%70-7466.7%15.3- 95.7100.0%
75+100.0%100.0%75+100.0%100.0%75+100.0%100.0%75+100.0%100.0%75+100.0%100.0%
Aware HIV+ statusWomenMenlinked to careWomenMenIn careWomenMenOn ARTWomenMenViral Load < 1,000 copies/mlWomenMen
15-1985.2%69.2%15-1982.1%69.2%15-1982.1%69.3%15-1982.1%69.2%15-1973.1%58.3%
20-2483.3%60.0%20-2481.5%75.0%20-2475.4%75.0%20-2473.9%75.0%20-2473.3%66.7%
25-2988.5%55.6%25-2987.4%55.6%25-2982.8%27.8%25-2981.6%27.8%25-2978.3%46.7%
30-3488.6%83.3%30-3488.5%83.3%30-3485.8%75.0%30-3485.8%75.0%30-3484.1%71.4%
35-3995.7%85.4%35-3992.5%80.0%35-3991.3%75.0%35-3991.3%75.0%35-3989.1%77.5%
40-4495.2%84.6%40-4495.5%80.8%40-4489.0%73.1%40-4487.8%73.1%40-4492.5%75.0%
45-4994.1%92.3%45-4994.1%84.6%45-4994.1%76.9%45-4994.1%76.9%45-4995.5%76.0%
50-5498.6%86.4%50-5498.6%86.4%50-5497.1%81.8%50-5497.1%81.8%50-5497.1%81.8%
55-5995.9%94.7%55-5997.9%89.5%55-5997.9%84.2%55-5997.9%84.2%55-5995.8%84.4%
60-6496.2%100.0%60-6492.3%100.0%60-6492.3%100.0%60-6492.3%100.0%60-64100.0%100.0%
65-6988.5%81.8%65-6992.3%81.8%65-6992.3%81.8%65-6992.3%81.8%65-6992.3%81.8%
70-7466.7%100.0%70-7466.7%100.0%70-7466.7%100.0%70-7466.7%100.0%70-7466.7%100.0%
75+100.0%100.0%75+100.0%100.0%75+100.0%100.0%75+100.0%100.0%75+100.0%100.0%
Women
Aware HIV+ statuslinked to careIn careOn ARTViral Load < 1,000 copies/ml15-1920-2425-2930-3435-3940-4445-4950-5455-59
15-19100%85.2%82.1%82.1%82.1%73.1%Aware HIV+ status85.2%83.3%88.5%88.6%95.7%95.2%94.1%98.6%95.9%
20-24100%83.3%81.5%75.4%73.9%73.3%linked to care82.1%81.5%87.4%88.5%92.5%95.5%94.1%98.6%97.9%
25-29100%88.5%87.4%82.8%81.6%78.3%In care82.1%75.4%82.8%85.8%91.3%89.0%94.1%97.1%97.9%
30-34100%88.6%88.5%85.8%85.8%84.1%On ART82.1%73.9%81.6%85.8%91.3%87.8%94.1%97.1%97.9%
35-39100%95.7%92.5%91.3%91.3%89.1%Viral Load < 1,000 copies/ml73.1%73.3%78.3%84.1%89.1%92.5%95.5%97.1%95.8%
40-44100%95.2%95.5%89.0%87.8%92.5%
45-49100%94.1%94.1%94.1%94.1%95.5%Men
50-54100%98.6%98.6%97.1%97.1%97.1%15-1920-2425-2930-3435-3940-4445-4950-5455-59
55-59100%95.9%97.9%97.9%97.9%95.8%Aware HIV+ status69.2%60.0%55.6%83.3%85.4%84.6%92.3%86.4%94.7%
60-64100%96.2%92.3%92.3%92.3%100.0%linked to care69.2%75.0%55.6%83.3%80.0%80.8%84.6%86.4%89.5%
65-69100%88.5%92.3%92.3%92.3%92.3%In care69.3%75.0%27.8%75.0%75.0%73.1%76.9%81.8%84.2%
70-74100%66.7%66.7%66.7%66.7%66.7%On ART69.2%75.0%27.8%75.0%75.0%73.1%76.9%81.8%84.2%
75+100%100.0%100.0%100.0%100.0%100.0%Viral Load < 1,000 copies/ml58.3%66.7%46.7%71.4%77.5%75.0%76.0%81.8%84.4%
Sheet3
15-19
20-24
25-29
30-34
35-39
40-44
45-49
50-54
55-59
Women
Sheet3 (2)
Aware HIV+ status
linked to care
In care
On ART
Viral Load < 1,000 copies/ml
Men
Sheet3 (3)
15-19
20-24
25-29
30-34
35-39
40-44
45-49
50-54
55-59
Men
prevalence
Aware HIV+ status
linked to care
In care
On ART
Viral Load < 1,000 copies/ml
Women
909090
Aware HIV+ statusWomenMenlinked to careWomenMenIn careWomenMenOn ARTWomenMenViral Load < 1,000 copies/mlWomenMen
15-1985.2%66.5- 94.369.2%40.7- 88.115-1982.1%63.6- 92.469.2%40.7- 88.115-1982.1%63.6- 92.469.3%40.7- 88.115-1982.1%63.6- 92.469.2%40.7- 88.115-1973.1%53.2- 86.658.3%30.6- 81.7
20-2483.3%72.3- 90.560.0%19.8- 90.120-2481.5%70.2- 89.275.0%23.5- 96.720-2475.4%63.5- 84.475.0%23.5- 96.720-2473.9%61.9- 83.175.0%23.5- 96.720-2473.3%60.8- 83.066.7%15.1- 95.7
25-2988.5%79.9- 93.755.6%32.9- 76.125-2987.4%78.6- 92.955.6%32.9- 76.125-2982.8%73.3- 89.327.8%12.0- 52.125-2981.6%72.0- 88.427.8%11.9- 52.125-2978.3%68.2- 85.946.7%23.9- 70 9
30-3488.6%81.3-93.383.3%67.4- 92.430-3488.5%81.2- 93.283.3%67.4- 92.430-3485.8%78.1- 91.275.0%58.4- 86.530-3485.8%78.1- 91.275.0%58.4- 86.530-3484.1%75.9- 89.971.4%54.4- 84.0
35-3995.7%89.1- 98.485.4%70.9- 93.335-3992.5%85.0- 96.480.0%64.7- 89.735-3991.3%83.5- 95.675.0%59.3- 86.135-3991.3%83.5- 95.675.0%59.3- 86.135-3989.1%81.0- 94.177.5%62.0- 87.9
40-4495.2%87.8- 98.284.6%65.3- 94.240-4495.5%87.8- 98.280.8%61.1- 91.840-4489.0%80.2- 94.273.1%53.1- 86.740-4487.8%78.8- 93.373.1%53.1- 86.740-4492.5%84.3- 96.675.0%54.2- 88.4
45-4994.1%85.3- 97.892.3%73.7- 98.145-4994.1%85.3- 87.884.6%65.3- 94.245-4994.1%85.3- 97.876.9%57.1- 89.345-4994.1%85.3- 97.876.9%57.1- 89.345-4995.5%87.0- 98.676.0%55.7- 88.9
50-5498.6%90.4- 99.886.4%65.0- 95.650-5498.6%90.4- 99.886.4%65.0- 95.650-5497.1%89.1- 99.381.8%60.2- 93.150-5497.1%89.1- 99.381.8%60.2- 93.150-5497.1%89.1- 99.381.8%60.2- 94.2
55-5995.9%85.1- 99.094.7%70.3- 99.355-5997.9%86.6- 99.789.5%66.0- 97.455-5997.9%86.6- 99.784.2%60.6- 94.955-5997.9%86.6- 99.784.2%60.6- 94.955-5995.8%84.8- 99.084.4%60.6- 94.9
60-6496.2%77.1- 99.5100.0%60-6492.3%73.9- 98.1100.0%60-6492.3%73.9- 98.1100.0%60-6492.3%73.9- 98.1100.0%60-64100.0%100.0%
65-6988.5%69.7- 96.281.8%49.0- 95.565-6992.3%73.9- 98.181.8%49.0- 95.565-6992.3%73.9- 98.181.8%49.0- 95.565-6992.3%73.9- 98.181.8%49.0- 95.565-6992.3%73.9- 98.181.8%49.0- 95.5
70-7466.7%15.3- 95.7100.0%70-7466.7%15.3- 95.7100.0%70-7466.7%15.3- 95.7100.0%70-7466.7%15.3- 95.7100.0%70-7466.7%15.3- 95.7100.0%
75+100.0%100.0%75+100.0%100.0%75+100.0%100.0%75+100.0%100.0%75+100.0%100.0%
Aware HIV+ statusWomenMenlinked to careWomenMenIn careWomenMenOn ARTWomenMenViral Load < 1,000 copies/mlWomenMen
15-1985.2%69.2%15-1982.1%69.2%15-1982.1%69.3%15-1982.1%69.2%15-1973.1%58.3%
20-2483.3%60.0%20-2481.5%75.0%20-2475.4%75.0%20-2473.9%75.0%20-2473.3%66.7%
25-2988.5%55.6%25-2987.4%55.6%25-2982.8%27.8%25-2981.6%27.8%25-2978.3%46.7%
30-3488.6%83.3%30-3488.5%83.3%30-3485.8%75.0%30-3485.8%75.0%30-3484.1%71.4%
35-3995.7%85.4%35-3992.5%80.0%35-3991.3%75.0%35-3991.3%75.0%35-3989.1%77.5%
40-4495.2%84.6%40-4495.5%80.8%40-4489.0%73.1%40-4487.8%73.1%40-4492.5%75.0%
45-4994.1%92.3%45-4994.1%84.6%45-4994.1%76.9%45-4994.1%76.9%45-4995.5%76.0%
50-5498.6%86.4%50-5498.6%86.4%50-5497.1%81.8%50-5497.1%81.8%50-5497.1%81.8%
55-5995.9%94.7%55-5997.9%89.5%55-5997.9%84.2%55-5997.9%84.2%55-5995.8%84.4%
60-6496.2%100.0%60-6492.3%100.0%60-6492.3%100.0%60-6492.3%100.0%60-64100.0%100.0%
65-6988.5%81.8%65-6992.3%81.8%65-6992.3%81.8%65-6992.3%81.8%65-6992.3%81.8%
70-7466.7%100.0%70-7466.7%100.0%70-7466.7%100.0%70-7466.7%100.0%70-7466.7%100.0%
75+100.0%100.0%75+100.0%100.0%75+100.0%100.0%75+100.0%100.0%75+100.0%100.0%
Women
Aware HIV+ statuslinked to careIn careOn ARTViral Load < 1,000 copies/ml15-1920-2425-2930-3435-3940-4445-4950-5455-59
15-19100%85.2%82.1%82.1%82.1%73.1%Aware HIV+ status85.2%83.3%88.5%88.6%95.7%95.2%94.1%98.6%95.9%
30-34100%88.6%88.5%85.8%85.8%84.1%On ART82.1%73.9%81.6%85.8%91.3%87.8%94.1%97.1%97.9%
35-39100%95.7%92.5%91.3%91.3%89.1%Viral Load < 1,000 copies/ml73.1%73.3%78.3%84.1%89.1%92.5%95.5%97.1%95.8%
40-44100%95.2%95.5%89.0%87.8%92.5%
45-49100%94.1%94.1%94.1%94.1%95.5%Men
50-54100%98.6%98.6%97.1%97.1%97.1%15-1920-2425-2930-3435-3940-4445-4950-5455-59
55-59100%95.9%97.9%97.9%97.9%95.8%Aware HIV+ status69.2%60.0%55.6%83.3%85.4%84.6%92.3%86.4%94.7%
70-74100%66.7%66.7%66.7%66.7%66.7%On ART69.2%75.0%27.8%75.0%75.0%73.1%76.9%81.8%84.2%
75+100%100.0%100.0%100.0%100.0%100.0%Viral Load < 1,000 copies/ml58.3%66.7%46.7%71.4%77.5%75.0%76.0%81.8%84.4%
909090
15-19
20-24
25-29
30-34
35-39
40-44
45-49
50-54
55-59
Women
HIV testing
15-19
20-24
25-29
30-34
35-39
40-44
45-49
50-54
55-59
Men
HIV testing (2)
Women
15-2930-4445- 59
Aware HIV+ status86.1%92.8%96.2%
On ART78.9%88.2%96.2%
Viral Load < 1,000 copies/ml75.7%88.2%96.2%
Men
15-2930-4445-59
Aware HIV+ status61.6%84.5%91.0%
On ART48.6%74.5%80.6%
Viral Load < 1,000 copies/ml53.3%74.8%80.3%
HIV testing (2)
000000
15-29
30-44
45- 59
Women
TBNumber of people
000000
15-29
30-44
45-59
Men
15-29
30-44
45- 59
%
15-29
30-44
45-59
Prevalence stratified by gender
Men20182013
20132018%95%CI%95%CI
15-191.80.4Overall26.424.9- 27.925.223.6- 26.9
20-244.42.6Women30.528.6- 32.530.929.0-32.9
25-2919.314.5Men18.416.3- 20.815.914.0- 18.0
30-3435.637.5
35-3945.543.6
40-4437.632.5
45-4936.638.8
50-5430.733.3
55-5916.732.2
Women
20132018
15-197.57.3
20-2425.919.2
25-2940.937.3
30-3456.544.4
35-3955.550.5
40-4449.448.8
45-4933.241.5
50-5426.634.3
55-5919.822.2
Overall
20132018
15-195.7
20-2413.3
25-2929.4
30-3442.5
35-3948.2
40-4443.6
45-4940.7
50-5434.1
55-5916.724.3
Author:infection a al naissance
Women 2013
Women 2018
Age Group
%
Men 2013
Men 2018
Age Group
%
OverallWomenMen
909090909090909090
201376.469.993.179.070.593.468.367.992.1
201890.894.895.292.296.196.485.890.290.8
Overall20132018
%95%CI
1st 9076.474.1–78.690.887.9- 93.0
2nd 9069.967.0–72.794.892.4- 96.5
3rd 9093.191.0–94.895.292.7- 96.9
Women20132018
%95%CI
1st 9079.076.4- 81.492.289.2- 94.5
2nd 9070.567.7- 73.296.193.6- 97.7
3rd 9093.491.1- 95.196.493.7- 97.9
Men20132018
%95%CI
1st 9068.363.1- 73.185.878.4- 91.0
2nd 9067.960.8- 74.290.282.7- 94.7
3rd 9092.186.0- 95.790.882.6- 95.4
Overall 15-59
OverallWomenMen
n%95%CIn%95%CIn%95%CI
20134,59881.479.8- 82.93,11088.486.8- 89.91,48869.867.2- 72.4
20183,28696.796.1- 97.32,16498.197.4- 98.6112294.292.7- 95.4
Age groupMenWomen
15-1993.0%94.5%
20-2496.8%99.4%
25-2996.8%99.6%
30-3494.8%99.6%
35-3995.7%99.5%
40-4491.4%99.4%
45-4994.0%99.4%
50-5489.4%97.5%
55-5993.2%96.0%
Men
Women
Age Group
%
Among negative 15-59
OverallWomenMen
n%95%CIn%95%CIn%95%CI
2013
20182,4099695.1- 96.71,49797.396.4- 98.091293.892.0- 95.2
Age groupMenWomen
15-1993.9%94.1%
20-2496.8%99.3%
25-2997.2%100.0%
30-3491.7%99.3%
35-3994.3%98.9%
40-4488.9%98.9%
45-4990.2%100.0%
50-5484.1%96.2%
55-5992.5%94.8%
Men
Women
Age Group
%
Number of people scereened with WHO questions
Number of particpants who answer at least once positively to one of the questions
Number of particpants who produce a sputum
Number of particpants with a TB resultSensitive to Izoniazid, Rifampicin, Ethambutol, Streptomycin
Number of participants who were told thay had TB
Number of participant with a current treatment
Number of participant with a previous treatment
Chart1
Aware HIV+ statusAware HIV+ statusAware HIV+ status
On ARTOn ARTOn ART
Viral Load < 1,000 copies/mlViral Load < 1,000 copies/mlViral Load < 1,000 copies/ml
15-29
30-44
45-59
%
0.616
0.845
0.91
0.486
0.745
0.806
0.533
0.748
0.803
909090
Cascade of care (%)15-59 years
20132018
AllWomenMenAllWomenMen
HIV +100%100%100%100%100%100%
Aware of HIV Status76.4%74.1- 78.679.0%76.4- 81.468.3%63.1- 73.1%89.7%87.5- 91.591.9%89.6- 93.882.5%76.7- 87.1
Linked to care71.0%68.6- 73.473.4%71.6- 76.960.4%54.2- 66.1%88.5%86.1- 90.491.1%88.7- 93.179.9%73.8- 84.9
In Care62.7%59.8- 65.666.5%63.5- 69.350.6%44.6- 56.6%84.5%81.9- 86.788.3%85.6- 90.672.1%65.5- 77.8
On ART (test and treat)53.5%50.6- 56.355.7%52.8- 58.546.3%40.5- 52.3%84.1%81.5- 86.487.9%85.1- 90.272.1%65.5- 77.8
Viral Load < 1,000 copies/ml57.4%54.6- 60.160.3%57.4- 63.147.9%41.7- 54.1%83.9%81.3- 86.387.2%84.3- 89.673.3%66.7- 79.1
20132018
HIV +100%100%
Aware of HIV Status76.4%89.7%
Linked to care71.0%88.5%
In Care62.7%84.5%
On ART (test and treat)53.5%84.1%
Viral Load < 1,000 copies/ml57.4%83.9%
OverallWomenMen
909090909090909090
%95%CI%95%CI%95%CI%95%CI%95%CI%95%CI%95%CI%95%CI%95%CI
201376.474.1- 78.669.967.0- 72.793.191.0- 94.879.076.4- 81.470.567.7- 73.293.491.1- 95.168.363.1- 73.1%67.960.8- 74.292.186.0- 95.7
201889.787.5- 91.593.593.5- 96.994.492.4- 95.991.989.6- 93.895.593.5- 96.995.092.8- 96.582.576.7- 87.186.480.3- 90.892.386.5- 95.7
2013 results1st 9076.4% (95% CI: 74.1–78.6)
2nd 9069.9% (95% CI: 67.0–72.7)
3rd 9093.1% (95% CI: 91.0–94.8)
909090
2013
2018
Sheet3
Aware HIV+ statusWomenMenlinked to careWomenMenIn careWomenMenOn ARTWomenMenViral Load < 1,000 copies/mlWomenMen
15-1985.2%66.5- 94.369.2%40.7- 88.115-1982.1%63.6- 92.469.2%40.7- 88.115-1982.1%63.6- 92.469.3%40.7- 88.115-1982.1%63.6- 92.469.2%40.7- 88.115-1973.1%53.2- 86.658.3%30.6- 81.7
20-2483.3%72.3- 90.560.0%19.8- 90.120-2481.5%70.2- 89.275.0%23.5- 96.720-2475.4%63.5- 84.475.0%23.5- 96.720-2473.9%61.9- 83.175.0%23.5- 96.720-2473.3%60.8- 83.066.7%15.1- 95.7
25-2988.5%79.9- 93.755.6%32.9- 76.125-2987.4%78.6- 92.955.6%32.9- 76.125-2982.8%73.3- 89.327.8%12.0- 52.125-2981.6%72.0- 88.427.8%11.9- 52.125-2978.3%68.2- 85.946.7%23.9- 70 9
30-3488.6%81.3-93.383.3%67.4- 92.430-3488.5%81.2- 93.283.3%67.4- 92.430-3485.8%78.1- 91.275.0%58.4- 86.530-3485.8%78.1- 91.275.0%58.4- 86.530-3484.1%75.9- 89.971.4%54.4- 84.0
35-3995.7%89.1- 98.485.4%70.9- 93.335-3992.5%85.0- 96.480.0%64.7- 89.735-3991.3%83.5- 95.675.0%59.3- 86.135-3991.3%83.5- 95.675.0%59.3- 86.135-3989.1%81.0- 94.177.5%62.0- 87.9
40-4495.2%87.8- 98.284.6%65.3- 94.240-4495.5%87.8- 98.280.8%61.1- 91.840-4489.0%80.2- 94.273.1%53.1- 86.740-4487.8%78.8- 93.373.1%53.1- 86.740-4492.5%84.3- 96.675.0%54.2- 88.4
45-4994.1%85.3- 97.892.3%73.7- 98.145-4994.1%85.3- 87.884.6%65.3- 94.245-4994.1%85.3- 97.876.9%57.1- 89.345-4994.1%85.3- 97.876.9%57.1- 89.345-4995.5%87.0- 98.676.0%55.7- 88.9
50-5498.6%90.4- 99.886.4%65.0- 95.650-5498.6%90.4- 99.886.4%65.0- 95.650-5497.1%89.1- 99.381.8%60.2- 93.150-5497.1%89.1- 99.381.8%60.2- 93.150-5497.1%89.1- 99.381.8%60.2- 94.2
55-5995.9%85.1- 99.094.7%70.3- 99.355-5997.9%86.6- 99.789.5%66.0- 97.455-5997.9%86.6- 99.784.2%60.6- 94.955-5997.9%86.6- 99.784.2%60.6- 94.955-5995.8%84.8- 99.084.4%60.6- 94.9
60-6496.2%77.1- 99.5100.0%60-6492.3%73.9- 98.1100.0%60-6492.3%73.9- 98.1100.0%60-6492.3%73.9- 98.1100.0%60-64100.0%100.0%
65-6988.5%69.7- 96.281.8%49.0- 95.565-6992.3%73.9- 98.181.8%49.0- 95.565-6992.3%73.9- 98.181.8%49.0- 95.565-6992.3%73.9- 98.181.8%49.0- 95.565-6992.3%73.9- 98.181.8%49.0- 95.5
70-7466.7%15.3- 95.7100.0%70-7466.7%15.3- 95.7100.0%70-7466.7%15.3- 95.7100.0%70-7466.7%15.3- 95.7100.0%70-7466.7%15.3- 95.7100.0%
75+100.0%100.0%75+100.0%100.0%75+100.0%100.0%75+100.0%100.0%75+100.0%100.0%
Aware HIV+ statusWomenMenlinked to careWomenMenIn careWomenMenOn ARTWomenMenViral Load < 1,000 copies/mlWomenMen
15-1985.2%69.2%15-1982.1%69.2%15-1982.1%69.3%15-1982.1%69.2%15-1973.1%58.3%
20-2483.3%60.0%20-2481.5%75.0%20-2475.4%75.0%20-2473.9%75.0%20-2473.3%66.7%
25-2988.5%55.6%25-2987.4%55.6%25-2982.8%27.8%25-2981.6%27.8%25-2978.3%46.7%
30-3488.6%83.3%30-3488.5%83.3%30-3485.8%75.0%30-3485.8%75.0%30-3484.1%71.4%
35-3995.7%85.4%35-3992.5%80.0%35-3991.3%75.0%35-3991.3%75.0%35-3989.1%77.5%
40-4495.2%84.6%40-4495.5%80.8%40-4489.0%73.1%40-4487.8%73.1%40-4492.5%75.0%
45-4994.1%92.3%45-4994.1%84.6%45-4994.1%76.9%45-4994.1%76.9%45-4995.5%76.0%
50-5498.6%86.4%50-5498.6%86.4%50-5497.1%81.8%50-5497.1%81.8%50-5497.1%81.8%
55-5995.9%94.7%55-5997.9%89.5%55-5997.9%84.2%55-5997.9%84.2%55-5995.8%84.4%
60-6496.2%100.0%60-6492.3%100.0%60-6492.3%100.0%60-6492.3%100.0%60-64100.0%100.0%
65-6988.5%81.8%65-6992.3%81.8%65-6992.3%81.8%65-6992.3%81.8%65-6992.3%81.8%
70-7466.7%100.0%70-7466.7%100.0%70-7466.7%100.0%70-7466.7%100.0%70-7466.7%100.0%
75+100.0%100.0%75+100.0%100.0%75+100.0%100.0%75+100.0%100.0%75+100.0%100.0%
Women
Aware HIV+ statuslinked to careIn careOn ARTViral Load < 1,000 copies/ml15-1920-2425-2930-3435-3940-4445-4950-5455-59
15-19100%85.2%82.1%82.1%82.1%73.1%Aware HIV+ status85.2%83.3%88.5%88.6%95.7%95.2%94.1%98.6%95.9%
20-24100%83.3%81.5%75.4%73.9%73.3%linked to care82.1%81.5%87.4%88.5%92.5%95.5%94.1%98.6%97.9%
25-29100%88.5%87.4%82.8%81.6%78.3%In care82.1%75.4%82.8%85.8%91.3%89.0%94.1%97.1%97.9%
30-34100%88.6%88.5%85.8%85.8%84.1%On ART82.1%73.9%81.6%85.8%91.3%87.8%94.1%97.1%97.9%
35-39100%95.7%92.5%91.3%91.3%89.1%Viral Load < 1,000 copies/ml73.1%73.3%78.3%84.1%89.1%92.5%95.5%97.1%95.8%
40-44100%95.2%95.5%89.0%87.8%92.5%
45-49100%94.1%94.1%94.1%94.1%95.5%Men
50-54100%98.6%98.6%97.1%97.1%97.1%15-1920-2425-2930-3435-3940-4445-4950-5455-59
55-59100%95.9%97.9%97.9%97.9%95.8%Aware HIV+ status69.2%60.0%55.6%83.3%85.4%84.6%92.3%86.4%94.7%
60-64100%96.2%92.3%92.3%92.3%100.0%linked to care69.2%75.0%55.6%83.3%80.0%80.8%84.6%86.4%89.5%
65-69100%88.5%92.3%92.3%92.3%92.3%In care69.3%75.0%27.8%75.0%75.0%73.1%76.9%81.8%84.2%
70-74100%66.7%66.7%66.7%66.7%66.7%On ART69.2%75.0%27.8%75.0%75.0%73.1%76.9%81.8%84.2%
75+100%100.0%100.0%100.0%100.0%100.0%Viral Load < 1,000 copies/ml58.3%66.7%46.7%71.4%77.5%75.0%76.0%81.8%84.4%
Sheet3
15-19
20-24
25-29
30-34
35-39
40-44
45-49
50-54
55-59
Women
Sheet3 (2)
Aware HIV+ status
linked to care
In care
On ART
Viral Load < 1,000 copies/ml
Men
Sheet3 (3)
15-19
20-24
25-29
30-34
35-39
40-44
45-49
50-54
55-59
Men
prevalence
Aware HIV+ status
linked to care
In care
On ART
Viral Load < 1,000 copies/ml
Women
909090
Aware HIV+ statusWomenMenlinked to careWomenMenIn careWomenMenOn ARTWomenMenViral Load < 1,000 copies/mlWomenMen
15-1985.2%66.5- 94.369.2%40.7- 88.115-1982.1%63.6- 92.469.2%40.7- 88.115-1982.1%63.6- 92.469.3%40.7- 88.115-1982.1%63.6- 92.469.2%40.7- 88.115-1973.1%53.2- 86.658.3%30.6- 81.7
20-2483.3%72.3- 90.560.0%19.8- 90.120-2481.5%70.2- 89.275.0%23.5- 96.720-2475.4%63.5- 84.475.0%23.5- 96.720-2473.9%61.9- 83.175.0%23.5- 96.720-2473.3%60.8- 83.066.7%15.1- 95.7
25-2988.5%79.9- 93.755.6%32.9- 76.125-2987.4%78.6- 92.955.6%32.9- 76.125-2982.8%73.3- 89.327.8%12.0- 52.125-2981.6%72.0- 88.427.8%11.9- 52.125-2978.3%68.2- 85.946.7%23.9- 70 9
30-3488.6%81.3-93.383.3%67.4- 92.430-3488.5%81.2- 93.283.3%67.4- 92.430-3485.8%78.1- 91.275.0%58.4- 86.530-3485.8%78.1- 91.275.0%58.4- 86.530-3484.1%75.9- 89.971.4%54.4- 84.0
35-3995.7%89.1- 98.485.4%70.9- 93.335-3992.5%85.0- 96.480.0%64.7- 89.735-3991.3%83.5- 95.675.0%59.3- 86.135-3991.3%83.5- 95.675.0%59.3- 86.135-3989.1%81.0- 94.177.5%62.0- 87.9
40-4495.2%87.8- 98.284.6%65.3- 94.240-4495.5%87.8- 98.280.8%61.1- 91.840-4489.0%80.2- 94.273.1%53.1- 86.740-4487.8%78.8- 93.373.1%53.1- 86.740-4492.5%84.3- 96.675.0%54.2- 88.4
45-4994.1%85.3- 97.892.3%73.7- 98.145-4994.1%85.3- 87.884.6%65.3- 94.245-4994.1%85.3- 97.876.9%57.1- 89.345-4994.1%85.3- 97.876.9%57.1- 89.345-4995.5%87.0- 98.676.0%55.7- 88.9
50-5498.6%90.4- 99.886.4%65.0- 95.650-5498.6%90.4- 99.886.4%65.0- 95.650-5497.1%89.1- 99.381.8%60.2- 93.150-5497.1%89.1- 99.381.8%60.2- 93.150-5497.1%89.1- 99.381.8%60.2- 94.2
55-5995.9%85.1- 99.094.7%70.3- 99.355-5997.9%86.6- 99.789.5%66.0- 97.455-5997.9%86.6- 99.784.2%60.6- 94.955-5997.9%86.6- 99.784.2%60.6- 94.955-5995.8%84.8- 99.084.4%60.6- 94.9
60-6496.2%77.1- 99.5100.0%60-6492.3%73.9- 98.1100.0%60-6492.3%73.9- 98.1100.0%60-6492.3%73.9- 98.1100.0%60-64100.0%100.0%
65-6988.5%69.7- 96.281.8%49.0- 95.565-6992.3%73.9- 98.181.8%49.0- 95.565-6992.3%73.9- 98.181.8%49.0- 95.565-6992.3%73.9- 98.181.8%49.0- 95.565-6992.3%73.9- 98.181.8%49.0- 95.5
70-7466.7%15.3- 95.7100.0%70-7466.7%15.3- 95.7100.0%70-7466.7%15.3- 95.7100.0%70-7466.7%15.3- 95.7100.0%70-7466.7%15.3- 95.7100.0%
75+100.0%100.0%75+100.0%100.0%75+100.0%100.0%75+100.0%100.0%75+100.0%100.0%
Aware HIV+ statusWomenMenlinked to careWomenMenIn careWomenMenOn ARTWomenMenViral Load < 1,000 copies/mlWomenMen
15-1985.2%69.2%15-1982.1%69.2%15-1982.1%69.3%15-1982.1%69.2%15-1973.1%58.3%
20-2483.3%60.0%20-2481.5%75.0%20-2475.4%75.0%20-2473.9%75.0%20-2473.3%66.7%
25-2988.5%55.6%25-2987.4%55.6%25-2982.8%27.8%25-2981.6%27.8%25-2978.3%46.7%
30-3488.6%83.3%30-3488.5%83.3%30-3485.8%75.0%30-3485.8%75.0%30-3484.1%71.4%
35-3995.7%85.4%35-3992.5%80.0%35-3991.3%75.0%35-3991.3%75.0%35-3989.1%77.5%
40-4495.2%84.6%40-4495.5%80.8%40-4489.0%73.1%40-4487.8%73.1%40-4492.5%75.0%
45-4994.1%92.3%45-4994.1%84.6%45-4994.1%76.9%45-4994.1%76.9%45-4995.5%76.0%
50-5498.6%86.4%50-5498.6%86.4%50-5497.1%81.8%50-5497.1%81.8%50-5497.1%81.8%
55-5995.9%94.7%55-5997.9%89.5%55-5997.9%84.2%55-5997.9%84.2%55-5995.8%84.4%
60-6496.2%100.0%60-6492.3%100.0%60-6492.3%100.0%60-6492.3%100.0%60-64100.0%100.0%
65-6988.5%81.8%65-6992.3%81.8%65-6992.3%81.8%65-6992.3%81.8%65-6992.3%81.8%
70-7466.7%100.0%70-7466.7%100.0%70-7466.7%100.0%70-7466.7%100.0%70-7466.7%100.0%
75+100.0%100.0%75+100.0%100.0%75+100.0%100.0%75+100.0%100.0%75+100.0%100.0%
Women
Aware HIV+ statuslinked to careIn careOn ARTViral Load < 1,000 copies/ml15-1920-2425-2930-3435-3940-4445-4950-5455-59
15-19100%85.2%82.1%82.1%82.1%73.1%Aware HIV+ status85.2%83.3%88.5%88.6%95.7%95.2%94.1%98.6%95.9%
30-34100%88.6%88.5%85.8%85.8%84.1%On ART82.1%73.9%81.6%85.8%91.3%87.8%94.1%97.1%97.9%
35-39100%95.7%92.5%91.3%91.3%89.1%Viral Load < 1,000 copies/ml73.1%73.3%78.3%84.1%89.1%92.5%95.5%97.1%95.8%
40-44100%95.2%95.5%89.0%87.8%92.5%
45-49100%94.1%94.1%94.1%94.1%95.5%Men
50-54100%98.6%98.6%97.1%97.1%97.1%15-1920-2425-2930-3435-3940-4445-4950-5455-59
55-59100%95.9%97.9%97.9%97.9%95.8%Aware HIV+ status69.2%60.0%55.6%83.3%85.4%84.6%92.3%86.4%94.7%
70-74100%66.7%66.7%66.7%66.7%66.7%On ART69.2%75.0%27.8%75.0%75.0%73.1%76.9%81.8%84.2%
75+100%100.0%100.0%100.0%100.0%100.0%Viral Load < 1,000 copies/ml58.3%66.7%46.7%71.4%77.5%75.0%76.0%81.8%84.4%
909090
15-19
20-24
25-29
30-34
35-39
40-44
45-49
50-54
55-59
Women
HIV testing
15-19
20-24
25-29
30-34
35-39
40-44
45-49
50-54
55-59
Men
HIV testing (2)
Women
15-2930-4445- 59
Aware HIV+ status86.1%92.8%96.2%
On ART78.9%88.2%96.2%
Viral Load < 1,000 copies/ml75.7%88.2%96.2%
Men
15-2930-4445-59
Aware HIV+ status61.6%84.5%91.0%
On ART48.6%74.5%80.6%
Viral Load < 1,000 copies/ml53.3%74.8%80.3%
HIV testing (2)
000000
15-29
30-44
45- 59
Women
TBNumber of people
000000
15-29
30-44
45-59
Men
15-29
30-44
45- 59
%
15-29
30-44
45-59
%
Prevalence stratified by gender
Men20182013
20132018%95%CI%95%CI
15-191.80.4Overall26.424.9- 27.925.223.6- 26.9
20-244.42.6Women30.528.6- 32.530.929.0-32.9
25-2919.314.5Men18.416.3- 20.815.914.0- 18.0
30-3435.637.5
35-3945.543.6
40-4437.632.5
45-4936.638.8
50-5430.733.3
55-5916.732.2
Women
20132018
15-197.57.3
20-2425.919.2
25-2940.937.3
30-3456.544.4
35-3955.550.5
40-4449.448.8
45-4933.241.5
50-5426.634.3
55-5919.822.2
Overall
20132018
15-195.7
20-2413.3
25-2929.4
30-3442.5
35-3948.2
40-4443.6
45-4940.7
50-5434.1
55-5916.724.3
Author:infection a al naissance
Women 2013
Women 2018
Age Group
%
Men 2013
Men 2018
Age Group
%
OverallWomenMen
909090909090909090
201376.469.993.179.070.593.468.367.992.1
201890.894.895.292.296.196.485.890.290.8
Overall20132018
%95%CI
1st 9076.474.1–78.690.887.9- 93.0
2nd 9069.967.0–72.794.892.4- 96.5
3rd 9093.191.0–94.895.292.7- 96.9
Women20132018
%95%CI
1st 9079.076.4- 81.492.289.2- 94.5
2nd 9070.567.7- 73.296.193.6- 97.7
3rd 9093.491.1- 95.196.493.7- 97.9
Men20132018
%95%CI
1st 9068.363.1- 73.185.878.4- 91.0
2nd 9067.960.8- 74.290.282.7- 94.7
3rd 9092.186.0- 95.790.882.6- 95.4
Overall 15-59
OverallWomenMen
n%95%CIn%95%CIn%95%CI
20134,59881.479.8- 82.93,11088.486.8- 89.91,48869.867.2- 72.4
20183,28696.796.1- 97.32,16498.197.4- 98.6112294.292.7- 95.4
Age groupMenWomen
15-1993.0%94.5%
20-2496.8%99.4%
25-2996.8%99.6%
30-3494.8%99.6%
35-3995.7%99.5%
40-4491.4%99.4%
45-4994.0%99.4%
50-5489.4%97.5%
55-5993.2%96.0%
Men
Women
Age Group
%
Among negative 15-59
OverallWomenMen
n%95%CIn%95%CIn%95%CI
2013
20182,4099695.1- 96.71,49797.396.4- 98.091293.892.0- 95.2
Age groupMenWomen
15-1993.9%94.1%
20-2496.8%99.3%
25-2997.2%100.0%
30-3491.7%99.3%
35-3994.3%98.9%
40-4488.9%98.9%
45-4990.2%100.0%
50-5484.1%96.2%
55-5992.5%94.8%
Men
Women
Age Group
%
Number of people scereened with WHO questions
Number of particpants who answer at least once positively to one of the questions
Number of particpants who produce a sputum
Number of particpants with a TB resultSensitive to Izoniazid, Rifampicin, Ethambutol, Streptomycin
Number of participants who were told thay had TB
Number of participant with a current treatment
Number of participant with a previous treatment
-
OPERATIONAL RESEARCH DAY, Brussels – 31 May 2019
0
10
20
30
40
50
60
70
%
Age group
2018
2013
Prevalence data Women
0
10
20
30
40
50
60
70
%
Age group
20182013
Men
Chart1
15-1915-1932.32.41.8
20-2420-244.63.83.33.1
25-2925-296.45.94.84.6
30-3430-346.166.26.4
35-3935-397.27.15.76
40-4440-447.57.47.17.1
45-4945-497.77.36.76.1
50-5450-546.96.26.15.3
55-5955-595.9564.8
2018
2013
Age group
%
7.4
7.6
19.2
26.3
37.3
41.9
44.4
57
50.5
56.7
48.8
47.7
41.5
32.7
34.3
25.4
22.2
19.9
mortality rate 15-59
Mortality rate among 15-59 2018
Among residents, XXXXX 60 adults aged 15-59 years had died in the past 12 months prior to the survey (since August 2017).
The mortality rate among the 15-59 was 12.4/1,000 persons-year (PY) overall, 7.4/1,000 PY for women and 20.6/1,000 PY for men.
HIV testing all participants
HIV testing delay among all participants 15-59 2013
WomenMenOverall
201320132013
%95%CI%95%CI%95%CI
≤ 6 months50.448.2-52.749.746.8-52.650.248.2-52.2
6- 12 months12.911.8-14.113.811.9-16.113.212.3-14.2
>12 months34.532.5-36.635.132.1-38.334.732.9-36.6
Don't know/ invalid dates2.21.7-2.81.30.8-2.11.91.5-2.4
Delay since last HIV testWomenMenTotal
n%n%n%
≤6 months82138.7327311,14836.1
>6 -12 months27312.917116.244414
>12 -24 months37017.422521.359518.7
>24 months64930.63273197630.7
Don't know100.560.6170.5
48.052.349.4
HIV testing HIV neg- no diagno
HIV testing delay among participants HIV negative or not diagnosed 15-59 2013
WomenMenOverall
201320132013
%95%CI%95%CI%95%CI
≤ 6 months58.656.1-61.15349.7-56.256.654.5-58.7
6- 12 months13.712.3-15.314.312.2-16.913.912.8-15.2
>12 months26.224.1-28.531.427.9-35.128.126.1-30.2
Don't know/ invalid dates1.41.0-2.11.30.7-2.21.41.0-1.9
Delay since last HIV testWomenMenTotal
n%n%n%
≤6 months76450.630534.61,06944.7
>6 -12 months24716.416118.340817.1
>12 -24 months29719.720923.750621.2
>24 months1961320022.739616.6
Don't know50.360.7110.5
32.746.437.8
HIV testing coverage
HIV testing coverage 15-59 2013
2013
HIV testing rate OverallWomenMenHIV testing rate OverallWomenMenParticipants who never got a HIV test
%95%CI%95%CI%95%CI%95%CIHIV testing rate OverallWomenmen
15-1980.076.0-83.568.764.2-72.915-2980.076.0-83.568.764.2-72.9nn
20-2494.091.8-95.771.967.6-75.930-4496.294.9-97.172.469.3-75.215-1922.024.046.0
25-2997.195.0-98.471.664.7-77.645-5991.689.9-93.177.974.1-81.320-246.015.021.0
30-3498.996.8-99.774.667.9-80.325-299.016.025.0
35-3996.192.1-98.181.773.6-87.8201830-343.07.010.0
40-4496.593.4-98.279.471.8-85.3HIV testing rate OverallWomenMen35-393.05.08.0
45-4990.884.6-94.777.668.0-84.9%95%CI%95%CI40-445.06.011.0
50-5489.484.6-93.471.661.9-79.715-2997.596.3- 98.394.892.9- 96.3245-498.04.012.0
55-5983.177.9-87.378.067.2-85.930-4499.598.5- 99.894.190.6- 96.450-5414.03.017.0
total91.089.7-92.172.770.3-75.045-5997.595.8- 98.592.287.4- 95.255-5919.05.024.0
Total8985174.0
Difference
HIV testing rate OverallWomenMen
%95%CI%95%CI
15-2917.526.192.9- 96.32
30-443.321.790.6- 96.4
45-595.914.387.4- 95.2
20182018
HIV testing rate OverallWomenDiffHIV testing rate OverallMenDiff
Age grp%95%CI%95%CIAge grp%95%CI%95%CI
15-1980.076.0-83.594.591.7- 96.414.515-1968.764.2-72.993.089.8-95.324.374.4
20-2494.091.8-95.799.497.7- 99.95.420-2471.967.6-75.996.893.1- 98.624.924.8
25-2997.195.0-98.499.097.1- 99.91.925-2971.664.7-77.696.891.7- 98.825.2
30-3498.996.8-99.799.697.3- 99.90.730-3474.667.9-80.394.888.1- 97.820.2
35-3996.192.1-98.199.596.2- 99.93.435-3981.773.6-87.895.789.2- 98.414.0
40-4496.593.4-98.299.496.0- 99.92.940-4479.471.8-85.391.483.0- 95.812.0
45-4990.884.6-94.799.495.9- 99.98.645-4977.668.0-84.994.085.1- 97.716.4
50-5489.484.6-93.497.594.2- 99.08.150-5471.661.9-79.789.479.4- 94.917.8
55-5983.177.9-87.396.092.4- 97.912.955-5978.067.2-85.993.183.0- 97.415.1
total91.089.7-92.1total72.770.3-75.0
Prevalence table
Prevalence among 15-59
20182013
WomenMenTotalWomenMenTotal
n%95%CIn%(95%CIn%95%CIn%95%CIn%95%CIn%95%CI
Age groupAge group
15-19287.45.1- 10.4133.82.2-6.4415.74.2- 7.615-19587.65.8-10.0121.70.9-3.2704.93.8-6.2
20-246619.215.4- 23.852.61.1-6.27113.310.7- 16.520-2416126.323.2-29.6195.03.2-7.818017.315.3-19.5
25-298737.331.4- 43.71814.59.3-21.910529.424.9- 34.425-2920341.937.3-46.75719.816.2-24.026033.630.3-37.0
30-3411444.438.4- 50.53637.928.7- 48.015042.637.5- 47.830-3417357.050.6-63.26436.328.6-44.823749.144.6-53.6
35-399350.543.4- 57.74143.643.0- 53.813448.242.4- 54.135-3915756.750.7-62.46145.436.0-55.021853.148.1-57.9
40-448348.841.4- 56.32733.323.9- 44.311043.837.8- 50.540-4412447.740.6-54.84533.621.9-47.616834.428.9-40.3
45-496841.534.2- 49.22638.827.9- 50.99440.734.5- 47.245-498632.726.6-39.44439.229.7-49.612027.322.6-32.6
50-546934.328.1- 41.22132.322.1- 44.69033.828.4- 39.750-547525.420.1-31.53432.423.7-42.610619.115.0-24.1
55-594922.217.2- 28.1183120.5- 44672419.4- 80.655-594819.915.1-25.93116.614.3-19.26425.724.2-27.3
OverallMenWomen
95% lower95% upper95% lower95% upper95% lower95% upper
201315-19-4.94.9201315-190.93.21.50.8201315-195.8102.41.8
20-24-17.317.320-243.27.82.81.820-2423.229.63.33.1
25-29-33.633.625-2916.2244.23.625-2937.346.74.84.6
30-34-49.149.130-3428.644.88.57.730-3450.663.26.26.4
35-39-53.153.135-3936559.69.435-3950.762.45.76.0
40-44-34.434.440-4421.947.614.011.740-4440.654.87.17.1
45-49-27.327.345-4929.749.610.49.545-4926.639.46.76.1
50-54-19.119.150-5423.742.610.28.750-5420.131.56.15.3
55-59-25.725.755-5914.319.22.62.355-5915.125.96.04.8
201815-194.27.61.91.5201815-192.26.42.61.6201815-195.110.43.02.3
20-2410.716.53.22.620-241.16.23.61.520-2415.423.84.63.8
25-2924.934.454.525-299.321.97.45.225-2931.443.76.45.9
30-3437.547.85.25.130-3428.748.010.19.230-3438.450.56.16.0
35-3942.454.15.95.835-3934.053.810.29.635-3943.457.77.27.1
40-4437.850.56.7640-4423.944.311.09.440-4441.456.37.57.4
45-4934.547.26.56.245-4927.950.912.110.945-4934.249.27.77.3
50-5428.439.75.95.450-5422.144.612.310.250-5428.141.26.96.2
55-5919.480.656.64.655-5920.544.013.010.555-5917.228.15.95.0
Prevalence table (2)
Prevalence among 15-59
2018
WomenMenTotal
Age group20182013Age group20182013Age group20182013
15-197.47.615-193.81.715-195.74.9
20-2419.226.320-242.65.020-2413.317.3
25-2937.341.925-2914.519.825-2929.433.6
30-3444.457.030-3437.936.330-3442.649.1
35-3950.556.735-3943.645.435-3948.253.1
40-4448.847.740-4433.333.640-4443.834.4
45-4941.532.745-4938.839.245-4940.727.3
50-5434.325.450-5432.332.450-5433.819.1
55-5922.219.955-593116.655-592425.7
OverallMenWomen
95% lower95% upper95% lower95% upper95% lower95% upper
201315-1900201315-190.93.21.50.8201315-195.8102.41.8
20-240020-243.27.82.81.820-2423.229.63.33.1
25-290025-2916.2244.23.625-2937.346.74.84.6
30-340030-3428.644.88.57.730-3450.663.26.26.4
35-390035-3936559.69.435-3950.762.45.76.0
40-440040-4421.947.614.011.740-4440.654.87.17.1
45-490045-4929.749.610.49.545-4926.639.46.76.1
50-540050-5423.742.610.28.750-5420.131.56.15.3
55-590055-5914.319.22.62.355-5915.125.96.04.8
201815-194.27.61.91.5201815-192.26.42.61.6201815-195.110.43.02.3
20-2410.716.53.22.620-241.16.23.61.520-2415.423.84.63.8
25-2924.934.454.525-299.321.97.45.225-2931.443.76.45.9
30-3437.547.85.25.130-3428.748.010.19.230-3438.450.56.16.0
35-3942.454.15.95.835-3934.053.810.29.635-3943.457.77.27.1
40-4437.850.56.7640-4423.944.311.09.440-4441.456.37.57.4
45-4934.547.26.56.245-4927.950.912.110.945-4934.249.27.77.3
50-5428.439.75.95.450-5422.144.612.310.250-5428.141.26.96.2
55-5919.480.656.64.655-5920.544.013.010.555-5917.228.15.95.0
Prevalence table (2)
32.32.41.8
4.63.83.33.1
6.45.94.84.6
6.166.26.4
7.27.15.76
7.57.47.17.1
7.77.36.76.1
6.96.26.15.3
5.9564.8
2018
2013
Prevalence 2
2013
median age of HIV participants34 (27-42)
median age of HIV women33 (26-42)
median age of HIV men36 (29-44)
Status awareness
Status awareness 20132018
awareWomenMenTotal
%95%CI%95%CI%95%CIWomenMen
15-2968.4%(54.7-79.4)61.0%29.9-85.167.254.5-77.815-29 years85.6%79.2- 90.0%61.1%44.4- 75.5
30-4469.4%(65.3-73.2)51.6%43.2-59.965.561.7-69.230-44 years93.1%89.5- 95.5%85.6%77.4- 91.2
45-5988.5%(85.2-91.2)78.8%70.9-85.0%85.882.1-88.845- 59 years96.8%93.0- 98.6%90.8%80.8- 95.2
Diff
17.2%0.1%
23.7%34.0%
8.3%12.0%
ART coverage
2013
ART coverage among all hiv positiveWomenMenTotal2018Diff
%95%CI%95%CI%95%CIWomenMenWomenMen
15-2934.6%23.7-47.226.8%9.5-56.3%33.3%23.7-44.415-29 years79.4%47.2%44.8%13.9%
30-4444.4%39.7-49.130.0%23.5-37.4%41.3%37.3-45.430-44 years88.2%75.5%43.8%34.2%
45-5970.0%65.9-73.959.0%50.2-67.2%67.0%62.6-71.145- 59 years96.2%80.0%26.2%13.0%
2nd 90
ART coverage among the ones who knew their statusWomenMenTotal
%95%CI%95%CI%95%CI
15-2949.1%33.3-65.144.0%19.0-72.5%48.4%34.4-62.6
30-4462.8%56.5-68.658.1%44.9-70.262.0%55.8-67.8
45-5978.6%74.5-82.275.2%66.8-82.1%77.7%73.7-81.3
VLS
VLS among all HIV positive 20132018Diff
VLSWomenMenTotalVLSWomenMen
%95%CI%95%CI%95%CI%95%CI%95%CIWomenMen
15-2934.5%23.6-47.226.8%9.5-56.333.2%23.7-44.315-2975.6%68.6-81.4%51.5%34.8- 67.9%41.1%18.3%
30-4451.3%46.7-55.931.0%24.2-38.946.9%43.0-50.830-4488.3%84.0- 91.6%75.5%66.2- 82.9%37.0%28.6%
45-5960.4%57.6-63.158.1%49.2-66.568.9%64.6-72.945-5996.2%92.2- 98.2%79.7%68.0- 87.9%35.8%10.8%
3rd 90
VLS among participants on art
VLSWomenMenTotal
%95%CI%95%CI%95%CI
15-2982.0%57.9-93.8100.0%84.462.0-94.7
30-4492.5%88.3-95.389.0%71.8-96.39287.6-94.9
45-5994.6%91.6-96.693.4%85.8-97.1%94.391.5-96.3
Sheet1
Chart1
15-1915-192.61.61.50.8
20-2420-243.61.52.81.8
25-2925-297.45.24.23.6
30-3430-3410.19.28.57.7
35-3935-3910.29.69.69.4
40-4440-44119.41411.7
45-4945-4912.110.910.49.5
50-5450-5412.310.210.28.7
55-5955-591310.52.62.3
2018
2013
Age group
%
3.8
1.7
2.6
5
14.5
19.8
37.9
36.3
43.6
45.4
33.3
33.6
38.8
39.2
32.3
32.4
31
16.6
mortality rate 15-59
Mortality rate among 15-59 2018
Among residents, XXXXX 60 adults aged 15-59 years had died in the past 12 months prior to the survey (since August 2017).
The mortality rate among the 15-59 was 12.4/1,000 persons-year (PY) overall, 7.4/1,000 PY for women and 20.6/1,000 PY for men.
HIV testing all participants
HIV testing delay among all participants 15-59 2013
WomenMenOverall
201320132013
%95%CI%95%CI%95%CI
≤ 6 months50.448.2-52.749.746.8-52.650.248.2-52.2
6- 12 months12.911.8-14.113.811.9-16.113.212.3-14.2
>12 months34.532.5-36.635.132.1-38.334.732.9-36.6
Don't know/ invalid dates2.21.7-2.81.30.8-2.11.91.5-2.4
Delay since last HIV testWomenMenTotal
n%n%n%
≤6 months82138.7327311,14836.1
>6 -12 months27312.917116.244414
>12 -24 months37017.422521.359518.7
>24 months64930.63273197630.7
Don't know100.560.6170.5
48.052.349.4
HIV testing HIV neg- no diagno
HIV testing delay among participants HIV negative or not diagnosed 15-59 2013
WomenMenOverall
201320132013
%95%CI%95%CI%95%CI
≤ 6 months58.656.1-61.15349.7-56.256.654.5-58.7
6- 12 months13.712.3-15.314.312.2-16.913.912.8-15.2
>12 months26.224.1-28.531.427.9-35.128.126.1-30.2
Don't know/ invalid dates1.41.0-2.11.30.7-2.21.41.0-1.9
Delay since last HIV testWomenMenTotal
n%n%n%
≤6 months76450.630534.61,06944.7
>6 -12 months24716.416118.340817.1
>12 -24 months29719.720923.750621.2
>24 months1961320022.739616.6
Don't know50.360.7110.5
32.746.437.8
HIV testing coverage
HIV testing coverage 15-59 2013
2013
HIV testing rate OverallWomenMenHIV testing rate OverallWomenMenParticipants who never got a HIV test
%95%CI%95%CI%95%CI%95%CIHIV testing rate OverallWomenmen
15-1980.076.0-83.568.764.2-72.915-2980.076.0-83.568.764.2-72.9nn
20-2494.091.8-95.771.967.6-75.930-4496.294.9-97.172.469.3-75.215-1922.024.046.0
25-2997.195.0-98.471.664.7-77.645-5991.689.9-93.177.974.1-81.320-246.015.021.0
30-3498.996.8-99.774.667.9-80.325-299.016.025.0
35-3996.192.1-98.181.773.6-87.8201830-343.07.010.0
40-4496.593.4-98.279.471.8-85.3HIV testing rate OverallWomenMen35-393.05.08.0
45-4990.884.6-94.777.668.0-84.9%95%CI%95%CI40-445.06.011.0
50-5489.484.6-93.471.661.9-79.715-2997.596.3- 98.394.892.9- 96.3245-498.04.012.0
55-5983.177.9-87.378.067.2-85.930-4499.598.5- 99.894.190.6- 96.450-5414.03.017.0
total91.089.7-92.172.770.3-75.045-5997.595.8- 98.592.287.4- 95.255-5919.05.024.0
Total8985174.0
Difference
HIV testing rate OverallWomenMen
%95%CI%95%CI
15-2917.526.192.9- 96.32
30-443.321.790.6- 96.4
45-595.914.387.4- 95.2
20182018
HIV testing rate OverallWomenDiffHIV testing rate OverallMenDiff
Age grp%95%CI%95%CIAge grp%95%CI%95%CI
15-1980.076.0-83.594.591.7- 96.414.515-1968.764.2-72.993.089.8-95.324.374.4
20-2494.091.8-95.799.497.7- 99.95.420-2471.967.6-75.996.893.1- 98.624.924.8
25-2997.195.0-98.499.097.1- 99.91.925-2971.664.7-77.696.891.7- 98.825.2
30-3498.996.8-99.799.697.3- 99.90.730-3474.667.9-80.394.888.1- 97.820.2
35-3996.192.1-98.199.596.2- 99.93.435-3981.773.6-87.895.789.2- 98.414.0
40-4496.593.4-98.299.496.0- 99.92.940-4479.471.8-85.391.483.0- 95.812.0
45-4990.884.6-94.799.495.9- 99.98.645-4977.668.0-84.994.085.1- 97.716.4
50-5489.484.6-93.497.594.2- 99.08.150-5471.661.9-79.789.479.4- 94.917.8
55-5983.177.9-87.396.092.4- 97.912.955-5978.067.2-85.993.183.0- 97.415.1
total91.089.7-92.1total72.770.3-75.0
Prevalence table
Prevalence among 15-59
20182013
WomenMenTotalWomenMenTotal
n%95%CIn%(95%CIn%95%CIn%95%CIn%95%CIn%95%CI
Age groupAge group
15-19287.45.1- 10.4133.82.2-6.4415.74.2- 7.615-19587.65.8-10.0121.70.9-3.2704.93.8-6.2
20-246619.215.4- 23.852.61.1-6.27113.310.7- 16.520-2416126.323.2-29.6195.03.2-7.818017.315.3-19.5
25-298737.331.4- 43.71814.59.3-21.910529.424.9- 34.425-2920341.937.3-46.75719.816.2-24.026033.630.3-37.0
30-3411444.438.4- 50.53637.928.7- 48.015042.637.5- 47.830-3417357.050.6-63.26436.328.6-44.823749.144.6-53.6
35-399350.543.4- 57.74143.643.0- 53.813448.242.4- 54.135-3915756.750.7-62.46145.436.0-55.021853.148.1-57.9
40-448348.841.4- 56.32733.323.9- 44.311043.837.8- 50.540-4412447.740.6-54.84533.621.9-47.616834.428.9-40.3
45-496841.534.2- 49.22638.827.9- 50.99440.734.5- 47.245-498632.726.6-39.44439.229.7-49.612027.322.6-32.6
50-546934.328.1- 41.22132.322.1- 44.69033.828.4- 39.750-547525.420.1-31.53432.423.7-42.610619.115.0-24.1
55-594922.217.2- 28.1183120.5- 44672419.4- 80.655-594819.915.1-25.93116.614.3-19.26425.724.2-27.3
OverallMenWomen
95% lower95% upper95% lower95% upper95% lower95% upper
201315-19-4.94.9201315-190.93.21.50.8201315-195.8102.41.8
20-24-17.317.320-243.27.82.81.820-2423.229.63.33.1
25-29-33.633.625-2916.2244.23.625-2937.346.74.84.6
30-34-49.149.130-3428.644.88.57.730-3450.663.26.26.4
35-39-53.153.135-3936559.69.435-3950.762.45.76.0
40-44-34.434.440-4421.947.614.011.740-4440.654.87.17.1
45-49-27.327.345-4929.749.610.49.545-4926.639.46.76.1
50-54-19.119.150-5423.742.610.28.750-5420.131.56.15.3
55-59-25.725.755-5914.319.22.62.355-5915.125.96.04.8
201815-194.27.61.91.5201815-192.26.42.61.6201815-195.110.43.02.3
20-2410.716.53.22.620-241.16.23.61.520-2415.423.84.63.8
25-2924.934.454.525-299.321.97.45.225-2931.443.76.45.9
30-3437.547.85.25.130-3428.748.010.19.230-3438.450.56.16.0
35-3942.454.15.95.835-3934.053.810.29.635-3943.457.77.27.1
40-4437.850.56.7640-4423.944.311.09.440-4441.456.37.57.4
45-4934.547.26.56.245-4927.950.912.110.945-4934.249.27.77.3
50-5428.439.75.95.450-5422.144.612.310.250-5428.141.26.96.2
55-5919.480.656.64.655-5920.544.013.010.555-5917.228.15.95.0
Prevalence table (2)
Prevalence among 15-59
2018
WomenMenTotal
Age group20182013Age group20182013Age group20182013
15-197.47.615-193.81.715-195.74.9
20-2419.226.320-242.65.020-2413.317.3
25-2937.341.925-2914.519.825-2929.433.6
30-3444.457.030-3437.936.330-3442.649.1
35-3950.556.735-3943.645.435-3948.253.1
40-4448.847.740-4433.333.640-4443.834.4
45-4941.532.745-4938.839.245-4940.727.3
50-5434.325.450-5432.332.450-5433.819.1
55-5922.219.955-593116.655-592425.7
OverallMenWomen
95% lower95% upper95% lower95% upper95% lower95% upper
201315-1900201315-190.93.21.50.8201315-195.8102.41.8
20-240020-243.27.82.81.820-2423.229.63.33.1
25-290025-2916.2244.23.625-2937.346.74.84.6
30-340030-3428.644.88.57.730-3450.663.26.26.4
35-390035-3936559.69.435-3950.762.45.76.0
40-440040-4421.947.614.011.740-4440.654.87.17.1
45-490045-4929.749.610.49.545-4926.639.46.76.1
50-540050-5423.742.610.28.750-5420.131.56.15.3
55-590055-5914.319.22.62.355-5915.125.96.04.8
201815-194.27.61.91.5201815-192.26.42.61.6201815-195.110.43.02.3
20-2410.716.53.22.620-241.16.23.61.520-2415.423.84.63.8
25-2924.934.454.525-299.321.97.45.225-2931.443.76.45.9
30-3437.547.85.25.130-3428.748.010.19.230-3438.450.56.16.0
35-3942.454.15.95.835-3934.053.810.29.635-3943.457.77.27.1
40-4437.850.56.7640-4423.944.311.09.440-4441.456.37.57.4
45-4934.547.26.56.245-4927.950.912.110.945-4934.249.27.77.3
50-5428.439.75.95.450-5422.144.612.310.250-5428.141.26.96.2
55-5919.480.656.64.655-5920.544.013.010.555-5917.228.15.95.0
Prevalence table (2)
32.32.41.8
4.63.83.33.1
6.45.94.84.6
6.166.26.4
7.27.15.76
7.57.47.17.1
7.77.36.76.1
6.96.26.15.3
5.9564.8
2018
2013
Prevalence 2
2.61.61.50.8
3.61.52.81.8
7.45.24.23.6
10.19.28.57.7
10.29.69.69.4
119.41411.7
12.110.910.49.5
12.310.210.28.7
1310.52.62.3
2018
2013
Men
Status awareness
2013
median age of HIV participants34 (27-42)
median age of HIV women33 (26-42)
median age of HIV men36 (29-44)
ART coverage
Status awareness 20132018
awareWomenMenTotal
%95%CI%95%CI%95%CIWomenMen
15-2968.4%(54.7-79.4)61.0%29.9-85.167.254.5-77.815-29 years85.6%79.2- 90.0%61.1%44.4- 75.5
30-4469.4%(65.3-73.2)51.6%43.2-59.965.561.7-69.230-44 years93.1%89.5- 95.5%85.6%77.4- 91.2
45-5988.5%(85.2-91.2)78.8%70.9-85.0%85.882.1-88.845- 59 years96.8%93.0- 98.6%90.8%80.8- 95.2
Diff
17.2%0.1%
23.7%34.0%
8.3%12.0%
VLS
2013
ART coverage among all hiv positiveWomenMenTotal2018Diff
%95%CI%95%CI%95%CIWomenMenWomenMen
15-2934.6%23.7-47.226.8%9.5-56.3%33.3%23.7-44.415-29 years79.4%47.2%44.8%13.9%
30-4444.4%39.7-49.130.0%23.5-37.4%41.3%37.3-45.430-44 years88.2%75.5%43.8%34.2%
45-5970.0%65.9-73.959.0%50.2-67.2%67.0%62.6-71.145- 59 years96.2%80.0%26.2%13.0%
2nd 90
ART coverage among the ones who knew their statusWomenMenTotal
%95%CI%95%CI%95%CI
15-2949.1%33.3-65.144.0%19.0-72.5%48.4%34.4-62.6
30-4462.8%56.5-68.658.1%44.9-70.262.0%55.8-67.8
45-5978.6%74.5-82.275.2%66.8-82.1%77.7%73.7-81.3
Sheet1
VLS among all HIV positive 20132018Diff
VLSWomenMenTotalVLSWomenMen
%95%CI%95%CI%95%CI%95%CI%95%CIWomenMen
15-2934.5%23.6-47.226.8%9.5-56.333.2%23.7-44.315-2975.6%68.6-81.4%51.5%34.8- 67.9%41.1%18.3%
30-4451.3%46.7-55.931.0%24.2-38.946.9%43.0-50.830-4488.3%84.0- 91.6%75.5%66.2- 82.9%37.0%28.6%
45-5960.4%57.6-63.158.1%49.2-66.568.9%64.6-72.945-5996.2%92.2- 98.2%79.7%68.0- 87.9%35.8%10.8%
3rd 90
VLS among participants on art
VLSWomenMenTotal
%95%CI%95%CI%95%CI
15-2982.0%57.9-93.8100.0%84.462.0-94.7
30-4492.5%88.3-95.389.0%71.8-96.39287.6-94.9
45-5994.6%91.6-96.693.4%85.8-97.1%94.391.5-96.3
-
OPERATIONAL RESEARCH DAY, Brussels – 31 May 2019
Incidence data
-
OPERATIONAL RESEARCH DAY, Brussels – 31 May 2019
Conclusions • It is feasible to achieve the 90-90-90 targets • MSF activities and national level policy changes contributed to
dramatic increase in viral suppression and ART coverage at the population level
• Community-based interventions were successful across the treatment cascade
• Data suggests a reduction of incidence at population level Similar trends have been reported in two other surveys
Ongoing challenges: • Males remain ‘hard to reach’ especially for first two ’90s’; • Adolescent girls and young womens remain at risk.
-
OPERATIONAL RESEARCH DAY, Brussels – 31 May 2019
Acknowledgements All the study participants and the Mbongolwane
Community
MHIPS team
Mbongolwane/ Eshowe team
MSF South Africa
DoH
MSF OCB
Epicentre
SAMU
CLS and NICD laboratories
Slide Number 1Slide Number 2Slide Number 3Slide Number 4Slide Number 5Slide Number 6Slide Number 7Slide Number 8Slide Number 9Slide Number 10Slide Number 11Slide Number 12Slide Number 13